BioCentury
ARTICLE | Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

Emerging Company Profile: Syncona’s Quell is developing more targeted Treg cell therapies

February 12, 2021 1:18 AM UTC

London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. 

On Thursday, Quell Therapeutics Ltd.’s founding investor, Syncona Ltd. (LSE:SYNC), led the close of an expanded series A round that should give the biotech enough runway to advance its lead cell therapy into the clinic and shore up its manufacturing capabilities. ...